Bausch & Lomb CorpBausch & Lomb Corp
Bausch & Lomb Corp

Bausch & Lomb Corp

BLCO
Health Care·Health Care Equipment & Supplies

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

British Columbia; Canada
Market cap
$6.1BNo data
Revenue
$5.1B+6.5% YoY
Net income
$-360M−13.6% YoY
Free cash flow
$-66M−11.9% YoY

Market

Listed stock
BLCOPriceNYSE
Loading…Loading…1Y

Financial performance

Revenue
$5.1B+6.5% YoY
Operating income
$113M−30.2% YoY
Net income
$-360M−13.6% YoY
Free cash flow
$-66M−11.9% YoY

Revenue, profit & cash trend

Revenue
Operating income
Net income
Free cash flow
Reference
Revenue: 2021 $3.8B, 2022 $3.8B, 2023 $4.1B, 2024 $4.8B, 2025 $5.1B. Operating income: 2021 $329M, 2022 $207M, 2023 $130M, 2024 $162M, 2025 $113M. Net income: 2021 $182M, 2022 $6M, 2023 $-260M, 2024 $-317M, 2025 $-360M. Free cash flow: 2021 $680M, 2022 $170M, 2023 $-198M, 2024 $-59M, 2025 $-66M. Reference line: Reference at $0.

Growth & profitability

Revenue growth
6.5%−909 bps YoY
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 $329M, 2022-12-31 $207M, 2023-12-31 $130M, 2024-12-31 $162M, 2025-12-31 $113M. Net income: 2021-12-31 $182M, 2022-12-31 $6M, 2023-12-31 $-260M, 2024-12-31 $-317M, 2025-12-31 $-360M. Free cash flow: 2021-12-31 $680M, 2022-12-31 $170M, 2023-12-31 $-198M, 2024-12-31 $-59M, 2025-12-31 $-66M

Growth heatmap

2022202320242025CAGR
Revenue
+0.1%
+10.0%
+15.6%
+6.5%
+7.9%
Gross profit
-100.9%
+14.3%
-27.8%
-8.7%
No data
Operating income
-37.1%
-37.2%
+24.6%
-30.2%
-23.4%
Free cash flow
-75.0%
-216.5%
+70.2%
-11.9%
No data

Earnings quality

Operating cash flow
$283M+22.0% YoY
Net income
$-360M−13.6% YoY
Free cash flow
$-66M−11.9% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 -79%, 2024-12-31 -73%, 2023-12-31 7%, 2022-12-31 5750%, 2021-12-31 480%. Free cash flow: 2025-12-31 18%, 2024-12-31 19%, 2023-12-31 76%, 2022-12-31 2833%, 2021-12-31 374%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data